Related Experiment Video
Updated: May 3, 2026

Experimental Metastasis and CTL Adoptive Transfer Immunotherapy Mouse Model
Published on: November 26, 2010
FSTL1 promotes bone metastasis by causing immune dysfunction
1Division of Cellular Signalling; Institute for Advanced Medical Research; Keio University School of Medicine; Tokyo, Japan.
Abstract:
In spite of significant advances in our understanding of the metastatic process, the relationship between the dissemination of primary neoplasms to the bones and antitumor immunity remains poorly understood. We have recently identified follistatin-like 1 (FSTL1), a soluble protein secreted by snail family zinc finger 1 (SNAI1)-expressing cancer cells, as a key determinant of bone metastasis that operates by inducing a systemic state of immune dysfunction.
Insights
Bone metastasis is poorly understood. Researchers found follistatin-like 1 (FSTL1) protein from cancer cells causes immune dysfunction, promoting bone tumor spread.
Area of Science:
- Oncology
- Immunology
- Cancer Metastasis
Background:
- The link between bone metastasis and antitumor immunity is unclear.
- Understanding cancer cell dissemination to bone is crucial for effective treatment.
Purpose of the Study:
- To investigate the role of secreted proteins in bone metastasis.
- To identify key factors driving immune dysfunction during cancer spread.
Main Methods:
- Analysis of protein expression in cancer cells.
- Investigating the effects of identified proteins on the immune system.
- Studying the impact on bone metastasis in preclinical models.
Main Results:
- Follistatin-like 1 (FSTL1), secreted by SNAI1-expressing cancer cells, was identified.
- FSTL1 was found to induce a systemic state of immune dysfunction.
- This immune dysfunction promotes the development of bone metastasis.
Conclusions:
- FSTL1 is a critical mediator of bone metastasis.
- Targeting FSTL1 may offer a novel therapeutic strategy to inhibit cancer spread and restore antitumor immunity.
Related Concept Videos
Metastasis
Epithelial-to-Mesenchymal Transition
The epithelial-to-mesenchymal transition or EMT is a developmental process commonly observed in wound healing, embryogenesis, and cancer metastasis. EMT is induced by transforming growth factor-beta (TGF-β) or receptor tyrosine kinase (RTK) ligands, which further...
The Tumor Microenvironment

